AIRESCAN Stock Review (23/12/2022)

Hi everyone.

On 23/12/2022, our system had provided a few picks and the results are as below:

MRNA – (Buy)  – Break-even

MRNA – (Buy) –  Loss

TEV – (Buy)  – Profit

The Dow Jones erased early losses and closed 170 points higher while the S&P 500 added 0.6% and Nasdaq added 0.21% on Friday with support from energy shares, as investors continued to digest the latest economic data for hints on the Federal Reserve’s path. 

Let’s review our stock picks on Friday.

Call for buy for MRNA which resulted in a break-even. Another call for buy resulted in a loss. Our system entered the market at $208.75 and the price hit stop loss at $202.75.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. 

Call for buy for TEVA which resulted in a profit. Our system entered the market at $9.18 and made a call to profit at $9.23.

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. 

Stay tuned for more of our stock picks.